On Nov 09, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $105 to $122.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $106 to $111.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $120.
Needham analyst Gil Blum maintains with a buy rating, and adjusts the target price from $96 to $105.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $122.
William Blair analyst Sami Corwin maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The assessment of Arcellx's anito-cel success probabilities has been revised upward after reviewing initial data from the iMMagine-1 Phase 2 trial in patients with relapsed/refractory multiple myeloma. Analysts perceive a significant opportunity for market share capture by anito-cel, initially among patients treated in later stages, and potentially extending to those in earlier stages if the current clinical outcomes are sustained.
The analyst noted that recent abstracts including initial Phase 2 data and additional Phase 1 follow-up data reinforce the competitive positioning and regulatory progress of pivotal-stage anito-cel in the treatment of multiple myeloma. Despite a recent decline in share price, which is viewed as a 'sell the news' reaction following a significant rise due to abstract anticipation, the analyst's perspective is that anito-cel is poised to secure a more formidable peak market share with increased probability of success.
The firm expressed a growing positive stance regarding the updated clinical data. The release of ASH abstracts online, which included initial data from the IMMagine-1 study, contributed to this view.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月9日，多家华尔街大行更新了$Arcellx (ACLX.US)$的评级，目标价介于105美元至122美元。
摩根士丹利分析师Judah Frommer维持买入评级，并将目标价从106美元上调至111美元。
Evercore分析师Cory Kasimov维持买入评级，维持目标价120美元。
Needham分析师Gil Blum维持买入评级，并将目标价从96美元上调至105美元。
斯迪富分析师Benjamin Burnett维持买入评级，维持目标价122美元。
威廉博莱分析师Sami Corwin维持买入评级。
此外，综合报道，$Arcellx (ACLX.US)$近期主要分析师观点如下：
Arcellx的anito-cel成功概率评估在审查了iMMagine-1阶段2试验中初步数据后被上调。分析师认为anito-cel在市场份额中有显著的机会，最初是在治疗晚期患者中，如果当前临床结果持续下去，潜在地延伸到早期患者。
分析师指出，最近的摘要包括初始2期数据和附加的1期后续数据，增强了关键阶段的anito-cel在多发性骨髓瘤治疗中的竞争定位和监管进展。尽管股价最近出现下跌，被视为对摘要预期带来的显著上涨做出的“卖出新闻”反应，但分析师认为，anito-cel有望在成功的概率增加下确保更具威望的市场份额。
该公司对更新的临床数据表达了愈发积极的立场。发布了包括IMMagine-1研究初期数据在内的ASH摘要在线，为这一观点提供了支持。
以下为今日7位分析师对$Arcellx (ACLX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
